Amgen Inc.
Synthesis of key intermediate of KRAS G12C inhibitor compound
Last updated:
Abstract:
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure ##STR00001## useful for the synthesis of compounds that target KRAS G12C mutations, such as ##STR00002##
Status:
Grant
Type:
Utility
Filling date:
15 Nov 2019
Issue date:
12 Apr 2022